bendamustine eg 2.5 mg/ml inj. sol. (pwdr., conc.) i.v. vial
eg sa-nv - bendamustine hydrochloride 25 mg - powder for concentrate for solution for infusion - 2,5 mg/ml - bendamustine hydrochloride 25 mg - bendamustine
bendamustine fresenius kabi 2.5 mg/ml inj. sol. (pwdr., conc.) i.v. vial
fresenius kabi sa-nv - bendamustine hydrochloride 25 mg - powder for concentrate for solution for infusion - 2,5 mg/ml - bendamustine hydrochloride 25 mg - bendamustine
bendamustine fresenius kabi 2.5 mg/ml inj. sol. (pwdr., conc.) i.v. vial
fresenius kabi sa-nv - bendamustine hydrochloride 25 mg - powder for concentrate for solution for infusion - 2,5 mg/ml - bendamustine hydrochloride 100 mg - bendamustine
levact 2.5 mg/ml inj. sol. (pwdr., conc.) i.v. vial
pharmaand gmbh - bendamustine hydrochloride 25 mg - eq. bendamustine 22,7 mg - powder for concentrate for solution for infusion - 2,5 mg/ml - bendamustine hydrochloride 25 mg - bendamustine
levact 2.5 mg/ml inj. sol. (pwdr., conc.) i.v. vial
pharmaand gmbh - bendamustine hydrochloride 25 mg - eq. bendamustine 22,7 mg - powder for concentrate for solution for infusion - 2,5 mg/ml - bendamustine hydrochloride 100 mg - bendamustine
bendamustine hydrochloride 2.5mg/ml powder for concentrate for solution for infusion
cherubino limited delf building, sliema road, gzira, gzr 1637, malta - powder for concentrate for solution for infusion - bendamustine hydrochloride 2.5 mg/ml - antineoplastic agents
bendamustine s.k. 100 mg
k.s.kim international (sk- pharma) ltd., israel - bendamustine as hydrochloride monohydrate - powder for concentrate for solution for infusion - bendamustine as hydrochloride monohydrate 100 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
bendamustine s.k. 25 mg
k.s.kim international (sk- pharma) ltd., israel - bendamustine as hydrochloride monohydrate - powder for concentrate for solution for infusion - bendamustine as hydrochloride monohydrate 25 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
demustin 100 mg
rafa laboratories ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg/vial - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
demustin 100 mg
rafa laboratories ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg/vial - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.